Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > CONSOLIDATION/DILUTION
View:
Post by Luxor101 on Nov 05, 2021 1:15pm

CONSOLIDATION/DILUTION

Consolidation followed by more dilution definitely hurts the shareholders. They supress any deals and tout how great things will be just to consolidate at a lower price. This management team are the same that got scammed by Mackie. These people are inept when it comes to the equity markets and we have said that from the start. Suggestions continue to not be heard and they think they know better than anyone and they do not. Look at the graphs they generated and now removed, revenue in Q4 2020. This is misleading and several statements by Elliott have been out right lies and now we should trust them to make the right decisions on a rollback. Look at the facts not suppositions made by this management crew. I believe they are already lined up to go on the NASDAQ and will not wait to see the shares appreciate as Elliott only enjoys a cheap valuation and will undoubtably issue himself more options at a discount so he does not get affected.
Comment by JackRedwood on Nov 05, 2021 2:54pm
M101 why are you posting under another username?  Plus you are making zero sense.  Positive vibes only please. 
Comment by DavidKingCanada on Nov 05, 2021 3:53pm
This post has been removed in accordance with Community Policy
Comment by Thenorth1990 on Nov 05, 2021 4:48pm
This post has been removed in accordance with Community Policy
Comment by Thenorth1990 on Nov 05, 2021 3:19pm
JR you have to understand that unitl the biogen approval it was positioned like once aducanumab is approved then there is a line up for partnership and investment banks are wiling to fund us. Didn't sound like they were going to dilute by issuing another 150 MN shares at discount, if that didn't happen.. we should be at 50 cents .. but we need cash too. The stock is like capped at 18 cents ...more  
Comment by DavidKingCanada on Nov 05, 2021 3:49pm
Thenorth, great post but lets keep a few points on hand; We as Shareholders have zero say in what the Boston Group will be doing in 2022. Sure maybe some people hold Millions of Shares on this Board but you will still have no Say. It's a penny stock with a very high upside and almost zero risk (unless you bought at 0.285 like JR. end game will be Nasdaq and for anyone who can make ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities